Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema ( TREAT ) registry taskforce
Journal of the European Academy of Dermatology and Venereology · 2025
DOI: 10.1111/jdv.20876 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von A H Musters und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Amsterdam Public Health, Infection and Immunity, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam,…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Registries. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The TREAT Registry Taskforce is a collaborative effort of international registries aiming to provide real‐world data on the long‐term efficacy, cost‐effectiveness and safety of systemic treatments and phototherapy for atopic eczema (AE).
Objectives
This study seeks to present a comprehensive overview of the demographics, prior systemic treatments, clinical characteristics and disease severity and burden at baseline among patients enrolled in seven TREAT registries. Moreover, the aim is to gain insight into the differences between the registries and to explore the current prescribing practices of various therapies for patients with AE across Europe.
Methods
Data from June 2016 to 31 October 2022, were collected from seven observational cohorts: A‐STAR (UK/Ireland), AtopyReg (Italy), Biobadatop (Spain), SCRATCH (Denmark), SwedAD (Sweden), TREATgermany (Germany) and TREAT NL/BE (Netherlands/Belgium).
Results
The analysis included 5337 patients, with a mean age of 39.1 years (6.3% paediatric, 54.4% male). Of these, 84.1% had previously received systemic treatments, primarily systemic corticosteroids (58.8%) and ciclosporin (39.0%), while 30.1% had undergone phototherapy. At enrolment, dupilumab was the most prescribed treatment (75.0%), followed by ciclosporin (7.8%) and Janus Kinase inhibitors (5.9%); only 1.7% started phototherapy. Baseline assessments showed that most patients had moderate (41.9%) to severe (30.1%) AE, with an average Eczema Area and Severity Index (EASI) score of 17.6. The Patient‐Oriented Eczema Measure (POEM) score averaged 17.2, indicating severe disease impact. The Dermatology Life Quality Index (DLQI) score averaged 13.4, and the Numerical Rating Scale (NRS) for itch was 6.4.
Conclusions
This pooled analysis from the TREAT Registry Taskforce highlights the variability and similarities in data collection across national registries, providing significant insights into the baseline characteristics of the patient population. It establishes a robust foundation for future analyses of key effectiveness and safety outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Amsterdam Public Health, Infection and Immunity, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
- Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, The Netherlands.
- National Heart Centre Singapore, Singapore City, Singapore.
- Department of Dermatology, Erasmus Universiteit Rotterdam, Rotterdam, The Netherlands.
- Center for Evidence-Based Health Care (ZEGV), Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
- Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
ORCID-Profile: A H Musters, D J Hijnen, S Weidinger, A Svedbom, I F Ruge, J P Thyssen, C Vestergaard, J M Carrascosa, L Stingeni, C Flohr
Zitieren
APA
Musters, A. H., Gerbens, L. A. A., van der Gang, L., Middelkamp-Hup, M. A., Ouwerkerk, W., Hijnen, D. J., Haufe, E., Heinrich, L., Werfel, T., Weidinger, S., Schmitt, J., Svedbom, A., Johansson, E. K., Bradley, M., von Kobyletzki, L. B., Vittrup, I., Ruge, I. F., Thyssen, J. P., Vestergaard, C., …, & A‐STAR, AtopyReg, BIOBADATOP, SCRATCH, SwedAD, TREATgermany and TREAT NL/BE registry teams (2025). Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema ( TREAT ) registry taskforce. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20876
Vancouver
Musters AH, Gerbens LAA, van der Gang L, Middelkamp-Hup MA, Ouwerkerk W, Hijnen DJ, et al. Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema ( TREAT ) registry taskforce. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20876
BibTeX
@article{Musters2025,
author = {Musters, A H and Gerbens, L A A and van der Gang, L and Middelkamp-Hup, M A and Ouwerkerk, W and Hijnen, D J and Haufe, E and Heinrich, L and Werfel, T and Weidinger, S and Schmitt, J and Svedbom, A and Johansson, E K and Bradley, M and von Kobyletzki, L B and Vittrup, I and Ruge, I F and Thyssen, J P and Vestergaard, C and Carrascosa, J M and de Vega, M and García-Doval, I and Chiricozzi, A and Stingeni, L and Calzavara-Pinton, P and Ardern-Jones, M R and Reynolds, N J and Flohr, C and Spuls, P I and A‐STAR, AtopyReg, BIOBADATOP, SCRATCH, SwedAD, TREATgermany and TREAT NL/BE registry teams, A‐STAR, AtopyReg, BIOBADATOP, SCRATCH, SwedAD, TREATgermany and TREAT NL/BE registry teams},
title = {Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema ( TREAT ) registry taskforce},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
doi = {10.1111/jdv.20876}
}
EUVIMED